Skip to main content
Cornell University


Friday, April 21, 2017 02:30 PM - 03:30 PM
Therapeutic Development Pathways Seminar

Therapeutic development costs are rising exponentially, with the average cost of each new FDA approved agent now estimated at $2.6 billion. In the era of precision medicine, with the need for many new agents and combinations of agents, this is obviously not a sustainable path to success. More accurate preclinical development is needed, as most new therapeutics fail during clinical trial testing. To that end, we have developed the Progressive Assessment of Therapeutics (PATh) program, which is designed to optimize each aspect of preclinical testing. Better in vitro modeling with 3-D organoid culture, better mouse genetic engineering with CRISPR/Cas9, patient derived xenograft cultures, and canine models all combine to form a more robust preclinical development platform. Utilizing cross-campus collaborations, we aim to accelerate therapeutic development while making it more accurate at the same time.  Examples of PATh’s application to development of new lymphoma therapeutics in development will be discussed.

"Cross-campus collaboration for experimental therapeutic development: PAThways to success"

Speaker: Kristy Richards, Ph.D., Associate Professor in the Department of Biomedical Sciences in the College of Veterinary Medicine, Cornell University, and Department of Medicine at Weill Cornell Medical College

This seminar is part of the BME 7900 Seminar Series - Spring 2017. Download flyer here.

226 Weill Hall
››› hCalendar